Practical Management of Biosimilar Use in Inflammatory Bowel Disease (IBD): A Global Survey and an International Delphi ConsensusShow others and affiliations
2023 (English)In: Journal of Clinical Medicine, E-ISSN 2077-0383, Vol. 12, no 19, article id 6350Article in journal (Refereed) Published
Abstract [en]
As the patents for biologic originator drugs expire, biosimilars are emerging as cost-effective alternatives within healthcare systems. Addressing various challenges in the clinical management of inflammatory bowel disease (IBD) remains crucial. To shed light on physicians' current knowledge, beliefs, practical approaches, and concerns related to biosimilar adoption-whether initiating a biosimilar, transitioning from an originator to a biosimilar, or switching between biosimilars (including multiple switches and reverse switching)-a global survey was conducted. Fifteen physicians with expertise in the field of IBD from 13 countries attended a virtual international consensus meeting to develop practical guidance regarding biosimilar adoption worldwide, considering the survey results. This consensus centered on 10 key statements covering biosimilar effectiveness, safety, indications, rationale, multiple switches, therapeutic drug monitoring of biosimilars, non-medical switching, and future perspectives. Ultimately, the consensus affirmed that biosimilars are equally effective and safe when compared to originator drugs. They are considered suitable for both biologic-naïve patients and those who have previously been treated with originator drugs, with cost reduction being the primary motivation for transitioning from an originator drug to a biosimilar.
Place, publisher, year, edition, pages
MDPI, 2023. Vol. 12, no 19, article id 6350
Keywords [en]
Crohn’s disease, IBD, bio-originators, biologic drug, biosimilars, economics, interchangeability, ulcerative colitis
National Category
Gastroenterology and Hepatology
Identifiers
URN: urn:nbn:se:oru:diva-108986DOI: 10.3390/jcm12196350ISI: 001094705100001PubMedID: 37834994Scopus ID: 2-s2.0-85173815239OAI: oai:DiVA.org:oru-108986DiVA, id: diva2:1805091
Note
The consensus was supported by Sandoz.
2023-10-162023-10-162024-04-08Bibliographically approved